New Details on the Revision of USP Chapter 1

Recommendation
27/28 May 2025
Implementation of a Cross Contamination Control Strategy
As already reported in the news "Second Revision of USP Chapter <1> Injections and Implanted Drug Products (Parenterals)-Product Quality Tests", USP's Chapter <1> "Injections and Implanted Drug Products (Parenterals)-Product Quality Tests' has been revised again. New information is now available.
The USP published these details on 25 March. The revised version now contains a table of contents for a better overview whereas the Product Performance Test at the end of the Chapter has been deleted. All details about the new version of USP's Chapter <1> can be found on the USP website.
The revised Chapter will become effective on May 1st, 2016.
Related GMP News
14.05.2025Process Validation and Pharmaceutical Water Deficiencies at a US Manufacturer
07.05.2025Another FDA Warning Letter for Indian API manufacturer
30.04.2025Cross-Contamination at Indian pharmaceutical manufacturer
23.04.2025Data Integrity Violations at an OTC Manufacturer
23.04.2025Warning Letter to Indian API Manufacturer due to Restricted Access